ArticleScientific reports2026
Syphilis epidemiology in Jordan: prevalence, incidence, and seroreversion from 15 years of laboratory-based data.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Syphilis is a health priority targeted for elimination by 2030, yet its global epidemiology remains insufficiently characterized. The study analyzed data from 25,630 adults aged ≥ 15 years who underwent syphilis testing in Jordan at Biolab Diagnostic Laboratories during 2010-2025. Cross-sectional and retrospective cohort analyses were used to estimate prevalence, temporal trends, patterns of rapid plasma reagin (RPR) and Treponema pallidum pallidum hemagglutination assay (TPHA) reactivity, associated risk factors, and incidence rate. Syphilis prevalence (ever RPR- or TPHA-reactive) was 0.9% (95% CI: 0.8-1.0%) overall and only 0.08% (95% CI: 0.05-0.10%) among those tested for visa-related medical screening. RPR reactivity was 0.5% (95% CI: 0.4-0.6%), and among RPR-reactive individuals, 79.2% (95% CI: 65.0-89.5%) were TPHA-reactive within 30 days. Outpatient or walk-in visits, doctor referrals, and laboratory referrals showed substantially higher reactivity than visa-related medical screening, whereas sex, governorate, insurance status, and testing year showed no significant associations. Cumulative syphilis incidence was 0.18% (95% CI: 0.04-0.72%) after two years of follow-up, with an incidence rate of 0.92 per 1,000 person-years (95% CI: 0.23-3.68). Syphilis prevalence and incidence in Jordan are relatively low, but with no evidence of decline over 15 years, indicating limited progress toward elimination targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.